Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Short-course Tislelizumab Combined With Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized, Controlled, Multicenter, Phase 3 Non-inferiority Clinical Trial

NCT07373990 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07373990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07373990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Short-course Tislelizumab Combined With Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized, Controlled, Multicenter, Phase 3 Non-inferiority Clinical Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 15, 2026
Completion date
December 31, 2030
Enrollment
418 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal cancer, nasopharyngeal cancinoma (npc)